MOH — authorised 15 September 2021
- Marketing authorisation holder: TAKEDA PHARMS USA
- Status: likely_approved
MOH authorised Exkivity on 15 September 2021
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. MOH authorised it on 15 September 2021.
TAKEDA PHARMS USA holds the Israeli marketing authorisation.